

New Hampshire Medicaid Fee-for-Service (FFS) Program

Prior Authorization/Non-Preferred Drug Approval Form

Anti-Fungal Medication for Onychomycosis

DATE OF MEDICATION REQUEST: /

SECTION I: PATIENT INFORMATION AND MEDICATIO	N REQUESTED								
LAST NAME:	FIRST NAME:								
MEDICAID ID NUMBER:	DATE OF BIRTH:								
GENDER: Male Female									
Drug Name	Strength								
Dosing Directions	Length of Therapy								
SECTION II: PRESCRIBER INFORMATION									
	FIRST NAME:								
SPECIALTY:	NPI NUMBER:								
PHONE NUMBER:	FAX NUMBER:								
SECTION III: CLINICAL HISTORY									
1. Patient's diagnosis:									
2. List pertinent laboratory test(s) or procedure(s), if a	applicable (KOH, PAS, Culture, etc.):								
PROCEDURE DATE OF PRO	OCEDURE FINDINGS								
/	/								
/	/								
/	/								
 Does the patient have immunosuppression, diabete compromise? 	es, or significant peripheral vascular Yes No								
a. If <i>Yes</i> , please list which diagnosis:									
4. Is the patient experiencing pain that limits normal a									
please use another page.	the decision-making process? If additional space is needed,								

/

(Form continued on next page.)





New Hampshire Medicaid Fee-for-Service (FFS) Program Prior Authorization/Non-Preferred Drug Approval Form

Anti-Fungal Medication for Onychomycosis

DATE OF MEDICATION REQUEST: /

PATIENT LAST NAME:							PATIENT FIRST NAME:																

If you are requesting a non-preferred product, complete Section IV. If not, then proceed to Prescriber's Signature.

SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERIA

CHAPTER 188 OF THE LAWS OF 2004 REQUIRES THAT MEDICAID ONLY COVER NON-PREFERRED DRUGS UPON A FINDING OF MEDICAL NECESSITY BY THE PRESCRIBING PHYSICIAN. CHAPTER 188 REQUIRES THAT YOU BASE YOUR DETERMINATION OF MEDICAL NECESSITY ON THE FOLLOWING CRITERIA.

Allergic reaction Drug-to-drug interaction

Please describe reaction:

Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:

Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to a preferred drug.

Age-specific indications. Please provide patient age and explain:

Unique clinical indication supported by FDA approval or peer-reviewed literature. Please explain and provide a reference:

Unacceptable clinical risk associated with therapeutic change. Please explain:

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PR	ESCR	IBER'S	SIGNAT	URE :	

DATE: _

